Congenital portosystemic shunts are rare malformations in which blood flowing through the portal vein, which normally delivers nutrient-rich blood from the intestines to the liver for processing, bypasses the liver entirely and drains directly into the systemic venous system. In this patient, the malformation was classified as a Park type I shunt, the category in which an abnormal vessel connects the portal circulation directly to the inferior vena cava. The consequences of such a shortcut are profound. Deprived of its full portal blood supply, the liver may fail to grow and develop normally, and a cascade of metabolic and hormonal disturbances can follow, because substances that would ordinarily be cleared or processed by the liver pass unfiltered into the general circulation. Among the most serious long-term consequences documented in the literature is an elevated risk of hepatic tumors, including hepatocellular carcinoma and, far more rarely, hepatoblastoma, the most common malignant liver tumor of early childhood.

Hepatoblastoma on its own is already a formidable diagnosis, typically arising in children under three years of age and demanding a combination of chemotherapy and surgical resection for any chance of cure. When the disease appears multifocally, meaning it involves several distinct regions of the liver rather than a single mass, surgical planning becomes considerably more complex. In this case the tumor was staged as PRETEXT stage III, a designation indicating that three of the four sections of the liver were involved, leaving only one contiguous healthy section. In a liver already compromised by a portosystemic shunt, with abnormal perfusion and potentially reduced functional reserve, the surgical team faced a clinical puzzle with no established playbook. The authors of the report emphasize that standardized diagnostic and therapeutic protocols for managing congenital portosystemic shunts accompanied by multifocal hepatoblastoma simply do not exist, forcing clinicians to improvise on the basis of first principles and close multidisciplinary collaboration.

The strategy the team ultimately pursued was deliberately sequenced. First, they performed an anatomical segment IV resection, removing the dominant tumor along with the entire liver segment in which it was based, an approach designed to secure clear margins rather than simply shelling out the visible mass. Critically, they combined this resection with concurrent closure of the congenital shunt in the same operative session. The shunt was occluded using a patent ductus arteriosus occluder, a device originally engineered to close abnormal openings between the great vessels of the heart, repurposed here to plug the aberrant portosystemic channel. Restoring normal portal blood flow to the liver is not merely a corrective maneuver for the vascular defect; it also matters for oncologic control, because re-establishing proper hepatic perfusion supports liver regeneration and function after major resection, and it removes the abnormal hemodynamic environment that is thought to contribute to tumor formation in these patients.

Once the dominant mass had been removed and the shunt closed, the team turned to the remaining multifocal tumor deposits. Instead of additional resections, which would have consumed precious liver volume in a child whose organ was already under strain, they deployed ultrasound-guided microwave ablation. Microwave ablation uses high-frequency electromagnetic waves to induce rapid heating within tumor tissue, causing coagulative necrosis at precisely targeted locations. Guided by real-time ultrasound, the surgeons could treat each residual lesion while sparing the surrounding healthy parenchyma, an advantage of particular importance in multifocal disease where the goal is to preserve as much functional liver as possible. The combination of anatomical resection for the largest lesion and ablation for the smaller deposits represents an elegant tissue-sparing division of labor that the authors argue may serve as a reference model for similar cases in the future.

Chemotherapy completed the treatment protocol, acting as a systemic safeguard against microscopic disease that imaging cannot detect. The specific regimen details illustrate the standard armamentarium of pediatric hepatoblastoma therapy, adapted to the patient’s recovery from major surgery. What distinguishes this case is not any single component, since each element, whether resection, ablation, chemotherapy, or shunt closure, is individually established in clinical practice, but the integration of all four into a coherent, coordinated plan executed across surgical oncology, interventional radiology, and pediatric oncology disciplines. The authors describe the protocol as safe and feasible based on their experience, and the outcome lends weight to that assessment: the shunt was successfully occluded, complete local tumor control was achieved, and the child has remained well through a ten-month follow-up period.

Surveillance in this case rested on three complementary pillars. Serial monitoring of alpha-fetoprotein, a protein produced abundantly by hepatoblastoma cells and normally present at high levels in newborns but declining through infancy, provided a sensitive biochemical indicator of any residual or recurrent tumor activity. Contrast-enhanced abdominal magnetic resonance imaging offered detailed anatomical assessment of the liver, allowing clinicians to verify that the ablated zones contained no viable tumor and that the liver itself was regenerating as expected after resection. Chest computed tomography completed the picture by excluding pulmonary metastases, the most common site of distant spread in hepatoblastoma. The convergence of a normalized alpha-fetoprotein trend, clean imaging, and the child’s clinical well-being at ten months constituted strong evidence of complete remission, though the authors are careful to frame the follow-up interval as meaningful rather than definitive, given the long horizon over which pediatric liver tumors can recur.

The broader significance of the case extends beyond a single patient. Congenital portosystemic shunts were once considered almost incidental findings, but accumulated evidence over recent decades has established that they carry real long-term risks, including hepatic encephalopathy, portopulmonary hypertension, liver nodules, and malignancy. The association between shunts and hepatoblastoma, while exceedingly rare, underscores the importance of longitudinal surveillance in children diagnosed with these vascular anomalies. This case also demonstrates that the traditional staging logic for hepatoblastoma, which assumes a normally perfused liver, must be adapted when a shunt alters hepatic hemodynamics. The Shenzhen team’s decision to address the shunt and the tumor simultaneously reflects a growing recognition that in complex congenital disease, fragmenting care among specialties that do not coordinate can compromise outcomes that an integrated plan could achieve.

Technically, the case highlights the versatility of devices and techniques crossing traditional disciplinary boundaries. The use of a patent ductus arteriosus occluder for shunt closure borrows from interventional cardiology, while microwave ablation is a technology shared between hepatology, radiology, and surgical oncology. Anatomical liver resection in a toddler demands precision given the small size of the liver and the limited tolerance for volume loss, and combining it with endovascular occlusion in the same anesthetic session required careful intraoperative planning. The report, supported by the Sanming Project of Medicine in Shenzhen and approved by the ethics committee of Shenzhen Children’s Hospital with written informed consent from the child’s legal guardians, is presented as an early-release, peer-reviewed, citable account intended to give clinicians confronting similar cases a documented precedent where none previously existed.

For the scientific and medical community, the message is twofold. First, children with congenital portosystemic shunts deserve vigilant, structured follow-up that includes liver imaging and tumor marker surveillance, because the risk of hepatic malignancy, though rare, is real and potentially curable when caught early. Second, when malignancy does arise in this setting, the experience from Shenzhen suggests that a single-stage approach combining anatomical resection of the dominant lesion, concurrent shunt closure, ultrasound-guided microwave ablation of satellite tumors, and adjuvant chemotherapy can deliver excellent local control without overwhelming the liver’s limited reserve. Ten months after surgery, a two-year-old who faced a combination of anomalies that most pediatric surgeons will never encounter is free of disease, and the medical literature has gained a template for the next patient unlucky enough to share the diagnosis.

Subject of Research: A rare pediatric case of congenital portosystemic shunt complicated by multifocal hepatoblastoma treated with multidisciplinary therapy.

Article Title: Multidisciplinary management of congenital portosystemic shunt complicated by multifocal hepatoblastoma: a case report

Article References: Multidisciplinary management of congenital portosystemic shunt complicated by multifocal hepatoblastoma: a case report. (n.d.). https://doi.org/10.1186/s12887-026-07743-0

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07743-0

Keywords: congenital portosystemic shunt, hepatoblastoma, pediatric liver tumor, microwave ablation, alpha-fetoprotein, multidisciplinary management, liver resection, Park type I shunt, PRETEXT staging, chemotherapy, BMC Pediatrics, case report

The study, published in the open-access journal Cancer Reports, rests on two variables that are already measured in every hepatocellular carcinoma workup: the number of tumors visible on imaging and the Model for End-Stage Liver Disease score, a laboratory index calculated from bilirubin, creatinine, and the international normalized ratio of prothrombin time that quantifies the functional reserve of a cirrhotic or damaged liver. The researchers drew on the rationale of the Japanese Society of Hepatology guidelines, which recommend considering liver resection for patients with multiple tumors when the tumor number is three or fewer, and reserving non-surgical treatments for patients with more than three tumors. They also incorporated the findings of a previous Italian study showing that a MELD score above nine signals an inadequate liver function reserve in patients undergoing liver resection, and that such a score was independently associated with postoperative liver decompensation, with an odds ratio of 2.26, a 95 percent confidence interval of 1.10 to 4.58, and a p value of 0.02.

From these two parameters the investigators constructed a two-tier classification of intermediate-stage disease that they labeled BCLC B1 and BCLC B2. Patients in the B1 category had to meet both criteria simultaneously, meaning a tumor number of three or fewer and a MELD score of nine or below, and these were defined as the ideal candidates for liver resection. Patients in the B2 category needed to satisfy only one of the two criteria, and these were defined as nonideal candidates for surgery. The cohort consisted of patients diagnosed with hepatocellular carcinoma between 2011 and 2021 who were managed at the study institution, all of whom had Child-Pugh class A liver function, the mildest functional class, and who had undergone either liver resection or transarterial chemoembolization. The protocol was approved by the Institutional Review Board of Kaohsiung Chang Gung Memorial Hospital under reference number 202201189B0, conformed to the Declaration of Helsinki, and the requirement for individual informed consent was waived.

The enrollment process captured a rich set of baseline variables for each patient, including age, sex, alpha-fetoprotein level, hepatitis B surface antigen status, antibody test results for hepatitis C virus, total bilirubin, creatinine, international normalized ratio, Child-Pugh classification, and MELD score. Under the staging definitions used in the study, BCLC stage B patients were those with Child-Pugh A or B liver disease and multifocal hepatocellular carcinoma beyond the Milan criteria, who did not have cancer-related symptoms and did not show macrovascular invasion or extrahepatic spread. The treatment algorithm at the institution reflected the realities of clinical practice in Taiwan: liver transplantation was an option for patients whose tumor burden fell within the University of California San Francisco criteria with a low alpha-fetoprotein level and clinically significant portal hypertension, the latter defined by a platelet count below ten to the ninth per liter with splenomegaly, the presence of varices, or portosystemic collateral vessels. Lobectomy was considered for tumors confined to one lobe, single-needle radiofrequency ablation was applied to multiple tumors smaller than three centimeters, and multipolar radiofrequency ablation was used for multiple tumors in which at least one measured between three and five centimeters. External beam radiation, systemic chemotherapy, or targeted therapy with sorafenib or lenvatinib was reserved for infiltrative hypovascular tumors or a tumor burden too high for embolization. Notably, targeted therapies and selective internal radiation therapy were not reimbursed by Taiwan’s National Health Insurance for patients with BCLC stage B disease, which constrained how often these modalities could be deployed.

When the researchers compared the baseline characteristics of the liver resection and chemoembolization subgroups, most variables were well balanced. Age, sex, the diameter of the largest nodule, alpha-fetoprotein level, and hepatitis B surface antigen positivity did not differ significantly between the groups. One exception stood out: the proportion of patients testing positive for hepatitis C virus antibodies was lower in the resection subgroup than in the embolization subgroup, a difference that reached statistical significance with a p value of 0.046. In one comparison of patient subgroups, the two arms also did not differ in alpha-fetoprotein levels of at least 400 nanograms per milliliter, which were recorded in 25 of 84 patients, or 29.8 percent, in one arm and 12 of 64 patients, or 18.8 percent, in the other, with a p value of 0.125.

The survival analysis produced the study’s central finding. Among patients classified as BCLC B1, the ideal surgical candidates, the median overall survival of patients undergoing liver resection was not reached during the observation period, while patients receiving transarterial chemoembolization survived a median of 3.9 years, with an interquartile range of 2.8 to 4.9 years. The difference was statistically significant, with a p value of 0.007. Strikingly, no patients in this group died within 90 days of treatment, underscoring that carefully selected surgical candidates not only lived longer but did so without an early postoperative mortality penalty. The Kaplan-Meier estimator and the log-rank test were used for these comparisons, all p values were two-tailed, and a p value below 0.05 was considered statistically significant.

The picture was different in the BCLC B2 group, the nonideal surgical candidates. There, two patients, or 2.5 percent, of those undergoing liver resection and four patients, or 1.9 percent, of those receiving chemoembolization died within 90 days of treatment, a difference that was not statistically significant with a p value of 0.671. The authors concluded from the combined evidence that patients with BCLC B1 disease are ideal candidates for liver resection, whereas those with BCLC B2 disease are not. This conclusion challenges the reflexive exclusion of surgery from intermediate-stage disease and, equally, challenges the assumption that all intermediate-stage patients are alike.

The study also engaged directly with competing frameworks for subdividing stage B disease. Spanish and Japanese investigations have used the up-to-seven criteria, in which the sum of tumor number and the size of the largest tumor in centimeters must not exceed seven, combined with Child-Pugh scores of 5 to 9, to stratify candidates. One cited study found a five-year recurrence rate of 25 percent for liver resection versus 60 percent for chemoembolization in a subgroup defined as Child-Pugh score 5 to 7 and within up-to-seven, with survival outcomes not differing between other subgroups, and concluded that resection provided better overall survival for that subgroup while survival was comparable for the others. A Korean study took a different tack, defining B2 disease as two to four oligonodular tumors with a largest tumor smaller than 10 centimeters, and found that resection produced better overall survival than embolization in that group, with a p value of 0.014, while survival did not differ significantly in the other groups. The Taiwanese authors argued that the up-to-seven criteria are not suitable for selecting patients for resection, because the very advantage of surgery is the removal of large tumors; in other words, tumor size should not disqualify a patient from resection. They illustrated the point with a concrete contrast: a patient with multiple small tumors, up to four in number with the largest measuring three centimeters and confined to one lobe, would fall within up-to-seven and be deemed an ideal resection candidate by the Spanish and Japanese criteria, yet in the authors’ experience such a patient would not be recommended for surgery. Conversely, their own tumor-number-based approach aligns with the Korean finding that resection suits patients with two to four tumors but not those with five or more.

The authors acknowledged that a proportion of BCLC B2 patients in their cohort may have had diffuse infiltrative hepatocellular carcinoma or a tumor burden too high for embolization, meaning that neither resection nor chemoembolization was truly suitable for them. Because systemic therapies for BCLC stage B disease were not reimbursed by Taiwan’s National Health Insurance, very few patients at this stage received such treatments, leaving a therapeutic gap that the study could not fill. The limitations of the work were stated plainly: it was retrospective and monocentric; it lacked data on severe comorbidities; cirrhosis data were not presented because the registry defined cirrhosis histologically for surgical patients and by imaging for non-surgical patients, and image-based definitions can be vague and subjective; and postoperative complication data, which are important for treatment decisions, were not available. The investigators also did not perform propensity score matching between the two treatment arms, because the groups had similar characteristics except for the lower prevalence of hepatitis C positivity among resection patients.

Even with those caveats, the study’s contribution is a practical one. By using just two variables that are available before any treatment begins, the image-defined tumor number and the MELD score, clinicians can preoperatively determine which subgroup of BCLC stage B patients should undergo liver resection and which should be directed toward transarterial chemoembolization. In an era when treatment options for intermediate-stage liver cancer are multiplying, from radioembolization to multipolar ablation to systemic therapy, a simple, reproducible two-parameter rule offers a way to bring order to a contested clinical space, and it gives surgeons and interventional radiologists a shared, evidence-based language for one of hepatocellular carcinoma’s most persistent decisions.

Subject of Research: Selection criteria using tumor number and MELD score for liver resection versus transarterial chemoembolization in intermediate-stage hepatocellular carcinoma

Article Title: Tumor Number and Model for End‐Stage Liver Disease Score as Selection Criteria for Resection or Embolization of Intermediate‐Stage Hepatocellular Carcinoma

Article References: Yen, Y.-H., Yong, C.-C., Liu, Y.-W., Li, W.-F., Wang, C.-C., & Lin, C.-Y. (2026). Tumor Number and Model for End‐Stage Liver Disease Score as Selection Criteria for Resection or Embolization of Intermediate‐Stage Hepatocellular Carcinoma. Cancer Reports, 9(9), Article e70697. https://doi.org/10.1002/cnr2.70697

Image Credits: AI Generated

DOI: 10.1002/cnr2.70697

Keywords: hepatocellular carcinoma, liver resection, transarterial chemoembolization, MELD score, BCLC staging, tumor number, overall survival, Child-Pugh class A, Taiwan, liver function reserve, up-to-seven criteria, retrospective study

The technique is a hybrid of two established concepts in interventional radiology. Radiation segmentectomy delivers an ablative dose of yttrium-90 glass microspheres directly into the artery feeding the tumor, achieving intense local tumor control. Radiation lobectomy, by contrast, treats the entire tumor-bearing lobe with a moderate dose that induces atrophy of the treated parenchyma, redirecting portal blood flow and growth signals to the untreated lobe, which compensates by enlarging. Modified radiation lobectomy combines these effects in a single procedure: a segmental or two-adjacent-segment boost above 190 Gy for tumor control, layered onto a lobar dose between 80 and 120 Gy to drive hypertrophy of the future liver remnant. In this study, the mean lobar prescribed dose was 198 plus or minus 58 Gy, with a mean segmental boost of 226 plus or minus 153 Gy, and patients received an average of 1.6 segmental doses.

The standard alternative for expanding a future liver remnant is portal vein embolization, which reliably induces hypertrophy but offers no direct tumor treatment, leaving a window during which cancer can progress. Transarterial chemoembolization controls tumors but produces less predictable liver growth and typically requires staged procedures. Modified radiation lobectomy uniquely merges tumor control and remnant augmentation in one session, which is why the researchers at an academic medical center in Colorado turned to it for patients whose tumors were unresectable by imaging criteria or biopsy, who had preserved liver function classified as Child-Pugh A, an Eastern Cooperative Oncology Group performance status of two or less, satisfactory lung shunt fractions, and no extrahepatic disease.

Between January 2019 and April 2022, fifteen consecutive patients underwent the procedure with the intention of bridging to curative resection. The cohort included seven women and eight men with a mean age of 66 years, ranging from 41 to 84. Seven had hepatocellular carcinoma, six of them at intermediate BCLC stage B and one at advanced stage C with portal vein tumor invasion, while eight had intrahepatic cholangiocarcinoma, five of whom had also received neoadjuvant gemcitabine-cisplatin chemotherapy. The mean index tumor size was a formidable 7.8 centimeters, with the largest measuring 16.2 centimeters. All patients had preserved hepatic function, and seven had underlying liver disease, including hepatitis C, alcohol-related injury, and metabolic dysfunction-associated steatotic liver disease.

Treatment planning was individualized through multidisciplinary tumor board discussion and surgical volumetric assessment. Earlier patients underwent planar macroaggregated albumin dosimetry with single-compartment calculations, while later patients benefited from SPECT/CT-based multicompartment personalized dosimetry using dedicated software. In that subgroup, the average perfused tumor absorbed dose reached 576 plus or minus 284 Gy, the average normal tissue dose was 206 plus or minus 95 Gy, the perfused fraction of the liver averaged 63 percent, and the cumulative lung absorbed dose averaged 16.4 Gy. Follow-up with triphasic CT or MRI occurred at one and three months and then at three-month intervals, with volumetric analysis at every time point using the Couinaud methodology and standardized future liver remnant calculations based on body surface area.

The results were remarkable on both fronts. Every one of the fifteen patients showed an objective tumor response by modified RECIST criteria at thirty days, with 40 percent achieving a complete response and 60 percent a partial response; by ninety days, the complete response rate rose to 53 percent as two additional partial responders converted. Meanwhile, the median future liver remnant increased by 12 percent at thirty days and 30 percent at sixty to ninety days. Median standardized future liver remnant climbed from 31 percent at baseline to 36 percent at one month and 40 percent by two to three months. Notably, hypertrophy was similar in cirrhotic and non-cirrhotic patients, and no difference emerged between hepatocellular carcinoma and cholangiocarcinoma, suggesting the volumetric effect is robust across liver conditions and tumor types.

Safety was equally encouraging. There were no major procedure-related complications, no grade three or higher hepatotoxicity by CTCAE version 5.0 criteria, and no cases of cholangitis, cholecystitis, gastric ulcers, pneumonitis, or radiation-induced liver disease. One patient experienced nausea and vomiting lasting ten days, and no patient required extended hospitalization or readmission within thirty days. This favorable profile likely reflects careful selection of patients with preserved baseline liver function and multidisciplinary evaluation, consistent with prior work showing that yttrium-90 treatment of more than 60 percent of the liver can be safe when an adequate functional remnant is maintained.

The surgical conversion rate was the standout finding. Twelve of the fifteen patients, or 80 percent, became technically eligible for curative-intent surgery, a figure substantially higher than the 16 to 20 percent conversion rates reported in earlier modified radiation lobectomy studies. Three patients were excluded by new disease progression in the contralateral liver or lungs, or inadequate remnant growth. Of the twelve eligible patients, one declined surgery and one resection was aborted because cholangiocarcinoma encased the hepatic vein confluence. Ultimately, ten patients underwent major hepatectomy, including four extended right and four standard right hepatectomies and one extended left hepatectomy, or liver transplantation in one case, at a mean of 122 plus or minus 77 days after radioembolization. Every completed resection achieved negative margins, an R0 outcome that is the surgical gold standard.

Pathology revealed a more nuanced picture. Among eight patients with available data, median tumor necrosis was 57.5 percent, ranging from 30 percent to more than 90 percent, and necrosis did not correlate with imaging response or absorbed dose. The authors attribute this variability to large, heterogeneous tumors with uneven microsphere distribution and to the relatively short interval between treatment and explantation. Despite this, overall survival after surgery remained 80 percent. Two patients with cholangiocarcinoma died within days of surgery from infectious complications, while the remaining eight resected patients showed no evidence of recurrence over an average follow-up of 39 months. Median overall survival was 61 months for hepatocellular carcinoma patients but only 19 months for those with cholangiocarcinoma, underscoring that tumor biology, not technical success, remains the dominant determinant of long-term outcome.

The study has clear limitations: it was retrospective, single-center, and small, with heterogeneous dosimetry methods and no comparator group receiving portal vein embolization or chemoembolization. Yet the message is compelling. Modified radiation lobectomy achieved universal tumor response, meaningful remnant hypertrophy, and an 80 percent surgical eligibility rate in patients whose tumors were once deemed unresectable, all with an excellent safety profile. The findings echo larger evidence, including the updated DOSISPHERE-01 analysis and the prospective PROACTIF cohort, showing that patients who reach curative surgery after yttrium-90 therapy enjoy substantially better survival than those managed nonoperatively. Larger prospective trials comparing modified radiation lobectomy with established bridging strategies are still needed, but for carefully selected patients with large primary liver cancers, this single-procedure approach may be transforming the boundary between inoperable and curable.

Subject of Research: Modified yttrium-90 radiation lobectomy as a bridge to curative surgery for primary liver cancer

Article Title: Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes

Article References: Malavia, M., Lindquist, J., Marchak, K., Eliason, G., Trivedi, P., & Casadaban, L. (2026). Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes. CVIR Oncology, 2(1), Article 29. https://doi.org/10.1007/s44343-026-00059-x

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00059-x

Keywords: modified radiation lobectomy, yttrium-90 radioembolization, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, future liver remnant hypertrophy, liver resection, radiation segmentectomy, portal vein embolization, surgical conversion, tumor response, interventional radiology, liver cancer

The study, led by Ashraf Nadeem, Yunfan Yang, Xinyan Li, and Kun Li of the Department of Hepatobiliary and Pancreatic Surgery at Zhongnan Hospital of Wuhan University, employed a frequentist network meta-analysis, a statistical framework that pools both direct comparisons and indirect evidence across a connected web of randomized trials. Because most adjuvant therapies for liver cancer have been tested only against observation or placebo rather than against each other, conventional pairwise meta-analysis cannot rank them. The network approach uses a shared common comparator—in this case, observation or placebo—as a statistical anchor, allowing the relative performance of treatments that have never faced each other in a trial to be estimated within a single model. Treatments were ranked using P-scores, which express the probability that one intervention outperforms another under the network model.

The evidence base was assembled through an exhaustive search of MEDLINE, Embase, CENTRAL, Web of Science, Scopus, regional databases, clinical trial registries, and conference proceedings covering trials published between January 2000 and December 2025. The investigators deliberately restricted their network to trials conducted exclusively in patients undergoing hepatic resection, excluding mixed populations that also included ablation or transplantation, in order to preserve clinical coherence and strengthen the transitivity assumption on which indirect comparisons depend. The review was prospectively registered in PROSPERO and reported according to the PRISMA 2020 statement and its network meta-analysis extension, with risk of bias assessed using the Cochrane Risk of Bias 2 tool.

The headline finding concerns overall survival. Three internal radiation and brachytherapy approaches dominated the survival hierarchy. Adjuvant iodine-125 brachytherapy showed the largest reduction in the hazard of death compared with observation, with a hazard ratio of 0.36 (95 percent confidence interval 0.17 to 0.78), followed by intensity-modulated radiation therapy, or IMRT, at a hazard ratio of 0.44 (0.23 to 0.86), and iodine-131-labeled metuximab, a radiolabeled antibody targeting HAb18G/CD147 on tumor cells, at 0.46 (0.28 to 0.77). In probabilistic terms, iodine-125 brachytherapy carried the highest P-score for overall survival at 0.86, ahead of IMRT at 0.78 and iodine-131-metuximab at 0.77. Conventional transarterial chemoembolization, long a mainstay of postoperative consolidation, retained activity with a hazard ratio of 0.71 (0.55 to 0.92) but was generally outperformed by the precision radiotherapy approaches.

The picture shifted when the outcome was recurrence-free survival, the primary endpoint of most adjuvant trials and typically the earliest signal of treatment failure. Here, the autologous formalin-fixed tumor vaccine, or AFTV, an immunotherapy prepared from a patient’s own resected tumor tissue, ranked first with a P-score of 0.92, followed by a combination of the traditional medicine Cidan capsule with transarterial chemoembolization at 0.90, iodine-125 brachytherapy at 0.84, and IMRT at 0.80. The divergence between the two hierarchies is not contradictory, the authors argue, but reflects differences in endpoint maturity and mechanism: recurrence events accrue earlier than deaths, and some strategies may suppress relapse long before any difference in survival fully matures.

The mechanistic reasoning behind these rankings is instructive. Early postoperative recurrence in hepatocellular carcinoma is frequently driven by microscopic residual disease, narrow resection margins, microvascular invasion, and venous dissemination—processes that concentrate relapse risk around the surgical bed and regional vascular pathways. IMRT is conceptually well suited to sterilizing this presumed microscopic disease in the postoperative field, whereas transarterial chemoembolization targets hypervascular visible tumor tissue through the arterial supply and is a less precise fit for the minimal residual disease setting. Meanwhile, the immune-based strategies operate systemically. Hepatocellular carcinoma typically arises in a chronically inflamed, immunologically dysregulated liver characterized by T-cell exhaustion and immune escape, and checkpoint inhibition with agents such as the PD-1 inhibitor sintilimab—which demonstrated a favorable benefit-risk profile in the network—aims to restore cytotoxic antitumor immunity against occult malignant clones throughout the remnant liver.

AFTV represents a different immunological logic altogether. Rather than amplifying pre-existing antitumor immunity, the autologous vaccine is designed to generate antigen-specific immune priming de novo, using formalin-fixed tumor tissue as a source of the full repertoire of tumor antigens in each individual patient. The authors note that this strategy is conceptually well matched to the adjuvant setting, where disease burden is minimal and immune containment is more achievable than in advanced disease. They are careful, however, to frame the finding as hypothesis-generating rather than definitive: the AFTV ranking rests on a single small phase II trial, mature overall survival data are lacking, and personalized vaccine platforms face practical challenges around standardization, scalability, and reproducibility across centers.

Safety signals across the 28 trials were reassuring. Grade 3 or higher adverse events were reported infrequently. Immune-related hepatitis of grade 3 occurred in 2 to 5 percent of patients receiving sintilimab, with no treatment-related deaths. Radiation-induced liver disease of grade 3 or worse was rare, affecting fewer than 1 percent of Child-Pugh A patients treated with IMRT. Post-embolization syndrome affected 5 to 10 percent of patients undergoing transarterial chemoembolization, and no grade 3 or higher events were reported for AFTV. The analysis also revealed that the strongest efficacy signals frequently came from clinically enriched high-risk populations: the sintilimab trial enrolled a cohort with 100 percent pathological microvascular invasion, the IMRT trial enrolled patients with 100 percent portal vein tumor thrombus, and the AFTV trial arose from a population with very high hepatitis B prevalence—features that matter for generalizability, since most included patients had hepatitis B virus-related disease and preserved liver function.

The authors are candid about the limitations of their work. The evidence network was largely star-shaped, with observation as the dominant comparator, meaning most comparisons between active treatments were estimated indirectly. Because the network contained no closed loops, formal consistency testing was not possible, and coherence rests entirely on the transitivity assumption. Hepatitis B prevalence ranged from 36 to 100 percent and microvascular invasion rates from 0 to 100 percent across trials, and meta-regression was infeasible given the small number of trials per covariate category. Landmark mixed-modality trials such as IMbrave050, which showed that adjuvant atezolizumab plus bevacizumab can reduce recurrence risk in high-risk patients after resection or ablation, could not be included because resection-specific estimates were not extractable. Evolving salvage therapies over the 26-year study window may also have influenced survival endpoints in older trials.

Nevertheless, the analysis points toward a future in which postoperative management of liver cancer is risk-adapted and mechanism-based rather than empiric. Precision radiotherapy may be most rational when relapse risk is concentrated in the surgical bed or vascular territory, while immune-based therapy may better serve patients whose recurrence risk is diffuse or systemic. The authors emphasize that not every patient should automatically receive adjuvant treatment; the strongest case exists for those with clearly elevated risk, such as microvascular invasion or tumor multiplicity. Large active-comparator randomized trials, standardized treatment-initiation windows, and biomarker-informed selection will be needed before a definitive standard emerges. Until then, this synthesis provides the clearest comparative map yet of a therapeutic landscape long defined by uncertainty.

Subject of Research: Comparative effectiveness of postoperative adjuvant therapies for hepatocellular carcinoma after curative resection, evaluated by network meta-analysis of randomized controlled trials

Article Title: Comparative efficacy and safety of postoperative adjuvant therapies after curative resection for hepatocellular carcinoma: a network meta-analysis

Article References: Nadeem, A., Yang, Y., Li, X., & Li, K. (2026). Comparative efficacy and safety of postoperative adjuvant therapies after curative resection for hepatocellular carcinoma: a network meta-analysis. Clinical Cancer Bulletin, 5(1), Article 14. https://doi.org/10.1007/s44272-026-00066-2

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00066-2

Keywords: hepatocellular carcinoma, network meta-analysis, adjuvant therapy, liver resection, iodine-125 brachytherapy, IMRT, iodine-131 metuximab, recurrence-free survival, overall survival, immunotherapy, tumor vaccine, TACE